PepGen Inc. (PEPG) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Boston, MA, アメリカ. 現CEOは James G. McArthur.
PEPG を有する IPO日 2022-05-06, 79 名の正社員, に上場 NASDAQ Global Select, 時価総額 $118.88M.
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
